406 related articles for article (PubMed ID: 29148406)
1. High 3-year golimumab survival in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: real world data from 328 patients.
Thomas K; Flouri I; Repa A; Fragiadaki K; Sfikakis PP; Koutsianas C; Kaltsonoudis E; Voulgari PV; Drosos AA; Petrikkou E; Sidiropoulos P; Vassilopoulos D
Clin Exp Rheumatol; 2018; 36(2):254-262. PubMed ID: 29148406
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany.
Krüger K; Burmester GR; Wassenberg S; Bohl-Bühler M; Thomas MH
BMJ Open; 2018 Jun; 8(6):e021082. PubMed ID: 29903793
[TBL] [Abstract][Full Text] [Related]
3. The persistence of golimumab compared to other tumour necrosis factor-α inhibitors in daily clinical practice for the treatment of rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: observations from the Slovenian nation-wide longitudinal registry of patients treated with biologic disease-modifying antirheumatic drugs-BioRx.si.
Rotar Ž; Tomšič M; Praprotnik S;
Clin Rheumatol; 2019 Feb; 38(2):297-305. PubMed ID: 30324406
[TBL] [Abstract][Full Text] [Related]
4. Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry.
Manara M; Caporali R; Favalli EG; Grosso V; Atzeni F; Sarzi Puttini P; Gorla R; Bazzani C; Fusaro E; Pellerito R; Rocchetta PA; Sinigaglia L
Clin Exp Rheumatol; 2017; 35(5):804-809. PubMed ID: 28770712
[TBL] [Abstract][Full Text] [Related]
5. Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis.
Iannone F; Santo L; Anelli MG; Bucci R; Semeraro A; Quarta L; D'Onofrio F; Marsico A; Carlino G; Casilli O; Cacciapaglia F; Zuccaro C; Falappone PC; Cantatore FP; Muratore M; Lapadula G
Semin Arthritis Rheum; 2017 Aug; 47(1):108-114. PubMed ID: 28216195
[TBL] [Abstract][Full Text] [Related]
6. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
[TBL] [Abstract][Full Text] [Related]
7. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
Boyce EG; Halilovic J; Stan-Ugbene O
Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
[TBL] [Abstract][Full Text] [Related]
8. Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany.
Krüger K; Burmester GR; Wassenberg S; Bohl-Bühler M; Thomas MH
Rheumatol Int; 2019 Jan; 39(1):131-140. PubMed ID: 30415451
[TBL] [Abstract][Full Text] [Related]
9. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire.
Barra L; Pope JE; Payne M
J Rheumatol; 2009 Jul; 36(7):1421-8. PubMed ID: 19487267
[TBL] [Abstract][Full Text] [Related]
10. Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences.
Favalli EG; Pontikaki I; Becciolini A; Biggioggero M; Ughi N; Romano M; Crotti C; Gattinara M; Gerloni V; Marchesoni A; Meroni PL
Clin Rheumatol; 2017 Aug; 36(8):1747-1755. PubMed ID: 28597133
[TBL] [Abstract][Full Text] [Related]
11. Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Husni ME; Deodhar A; Schwartzman S; Chakravarty SD; Hsia EC; Leu JH; Zhou Y; Lo KH; Kavanaugh A
Arthritis Res Ther; 2022 Mar; 24(1):73. PubMed ID: 35313978
[TBL] [Abstract][Full Text] [Related]
12. The efficacy and safety of golimumab in the treatment of arthritis.
Fleischmann R
Expert Opin Biol Ther; 2010 Jul; 10(7):1131-43. PubMed ID: 20504106
[TBL] [Abstract][Full Text] [Related]
13. Golimumab: a new anti-TNF-alpha agent for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.
Voulgari PV
Expert Rev Clin Immunol; 2010 Sep; 6(5):721-33. PubMed ID: 20828280
[TBL] [Abstract][Full Text] [Related]
14. Biologics and cardiovascular events in inflammatory arthritis: a prospective national cohort study.
Lee JL; Sinnathurai P; Buchbinder R; Hill C; Lassere M; March L
Arthritis Res Ther; 2018 Aug; 20(1):171. PubMed ID: 30086795
[TBL] [Abstract][Full Text] [Related]
15. Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
Kay J; Fleischmann R; Keystone E; Hsia EC; Hsu B; Mack M; Goldstein N; Braun J; Kavanaugh A
Ann Rheum Dis; 2015 Mar; 74(3):538-46. PubMed ID: 24344160
[TBL] [Abstract][Full Text] [Related]
16. Clinical efficacy and adverse effects of golimumab in the treatment of rheumatoid arthritis.
Chovel-Sella A; Karplus R; Sella T; Amital H
Isr Med Assoc J; 2012 Jun; 14(6):390-4. PubMed ID: 22891404
[TBL] [Abstract][Full Text] [Related]
17. Long-term golimumab persistence: Five-year treatment retention data pooled from pivotal Phase III clinical trials in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Weinstein CLJ; Meehan AG; Lin J; Briscoe SD; Govoni M
Clin Rheumatol; 2023 Dec; 42(12):3397-3405. PubMed ID: 37751000
[TBL] [Abstract][Full Text] [Related]
18. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
19. Five-year Safety Data from 5 Clinical Trials of Subcutaneous Golimumab in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis.
Kay J; Fleischmann R; Keystone E; Hsia EC; Hsu B; Zhou Y; Goldstein N; Braun J
J Rheumatol; 2016 Dec; 43(12):2120-2130. PubMed ID: 27803138
[TBL] [Abstract][Full Text] [Related]
20. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
Martinez-Cutillas J; Alerany-Pardo C; Borrás-Blasco J; Broto-Sumalla A; Burgos-SanJosé A; Climent-Bolta C; Escudero-Vilaplana V; Fernández-Fuente MA; Ferrit-Martin M; Gómez-Germá P; Martínez-Sesmero JM; Mayorga-Pérez J; Menchén-Viso B; Merino-Alonso J; Polache-Vengud J; Sánchez-Guerrero A
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):851-8. PubMed ID: 25972066
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
